EFFECT OF AVITROL BAITING ON BIRD DAMAGE TO RIPENING SUNFLOWER WITHIN A 144-SECTION BLOCK OF NORTH DAKOTA

The chemical frightening agent 4-aminopyridine (4-AP) has been repeatedly tested as a means of protecting both ripening corn (De Grazio et al. 1971, 1972; Besser et al. 1973; Besser 1976; Dolbeer et al. 1976; Stickley et al. 1972, 1976; Woronecki et al. 1979) and sunflower (Besser and Guarino 1976; Besser and Pfeifer 1978; Henne et al. 1979; Besser et al. in press) from depredating blackbirds. It was reported that less than one percent of a flock need ingest the treated baits and respond with distress symptoms in order to move birds from a corn field (De Grazio et al. 1972) or even shift roosting aggregations from night roosts (Cummings 1979). However, there is still conflicting evidence as to whether frightened blackbirds will subsequently avoid nearby fields, or even the same treated fields, resulting in efficient protection. The efficacy of 4-AP has not been resolved because of questions about the presentation and formulation of the treated baits and the difficulty of conducting a valid, unambiguous field test. This study was a large-scale evaluation of AvitroⓇ (HCI) FC-Corn Chops-99S1, where all commercial sunflower fields were monitored within a 144-sq mi block centered around a major concentration of roosting blackbirds; and all those fields with significant bird pressure were baited. The test was designed to answer two questions: can selective baiting (1) reduce damage overall when compared with pre-treatment damage from 1981, and (2) disperse it within the block? In other words, can the treatment keep blackbirds out of preferred fields? If so, is the result an overall reduction in damage within the surrounding area, or is it a redistribution of the damage

Cryptic, sympatric diversity in Tegu lizards of the Tupinambis teguixin Group (Squamata, Sauria, Teiidae) and the description of three new species

Tegus of the genera Tupinambis and Salvator are the largest Neotropical lizards and the most exploited clade of Neotropical reptiles. For three decades more than 34 million tegu skins were in trade, about 1.02 million per year. The genus Tupinambis is distributed in South America east of the Andes, and currently contains four recognized species, three of which are found only in Brazil. However, the type species of the genus, T. teguixin, is known from Bolivia, Brazil, Colombia, Ecuador, French Guyana, Guyana, Peru, Suriname, Trinidad and Tobago, and Venezuela (including the Isla de Margarita). Here we present molecular and morphological evidence that this species is genetically divergent across its range and identify four distinct clades some of which are sympatric. The occurrence of cryptic sympatric species undoubtedly exacerbated the nomenclatural problems of the past. We discuss the species supported by molecular and morphological evidence and increase the number of species in the genus Tupinambis to seven. The four members of the T. teguixin group continue to be confused with Salvator merianae, despite having a distinctly different morphology and reproductive mode. All members of the genus Tupinambis are CITES Appendix II. Yet, they continue to be heavily exploited, under studied, and confused in the minds of the public, conservationists, and scientists

New developments in aerosol measurements using stellar photometry

The idea of using stellar photometry for atmospheric monitoring for optical experiments in highenergy astrophysics is seemingly straightforward, but reaching high precision of the order of 0.01 in the determination of the vertical aerosol optical depth (VAOD) has proven difficult. Wide-field photometry over a large span of altitudes allows a fast determination of VAOD independently of the absolute calibration of the system, while providing this calibration as a useful by-product. Using several years of data taken by the FRAM (F/(Ph)otometric Robotic Atmospheric Monitor) telescope at the Pierre Auger Observatory in Argentina and about a year of data taken by a similar instrument deployed at the planned future Southern site of the Cherenkov Telescope Array in Chile, we have developed methods to improve the precision of this measurement technique towards and possibly beyond the 0.01 mark. Detailed laboratory measurements of the response of the whole system to both the spectrum and intensity of incoming light have proven indispensable in this analysis as the usual assumption of linearity of the CCD detectors is not valid anymore for the conditions of the observations

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation

Recruitment of monocytic myeloid-derived suppressor cells (MDSCs) and differentiation of tumor-associated macrophages (TAMs) are the major factors contributing to tumor progression and metastasis. We demonstrated that differentiation of TAMs in tumor site from monocytic precursors was controlled by downregulation of the activity of the transcription factor STAT3. Decreased STAT3 activity was caused by hypoxia and affected all myeloid cells but was not observed in tumor cells. Upregulation of CD45 tyrosine phosphatase activity in MDSCs exposed to hypoxia in tumor site was responsible for downregulation of STAT3. This effect was mediated by the disruption of CD45 protein dimerization regulated by sialic acid. Thus, STAT3 has a unique function in the tumor environment in controlling the differentiation of MDSC into TAM, and its regulatory pathway could be a potential target for therapy

Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study

PURPOSE: Programmed cell death-1 (PD-1) receptor inhibitors have shown efficacy in head and neck squamous cell carcinoma (HNSCC), but treatment failure or secondary resistance occurs in most patients. In preclinical murine carcinoma models, inhibition of Bruton\u27s tyrosine kinase (BTK) induces myeloid cell reprogramming that subsequently bolsters CD8+ T cell responses, resulting in enhanced antitumor activity. This phase 2, multicenter, open-label, randomized study evaluated pembrolizumab (anti-PD-1 monoclonal antibody) plus acalabrutinib (BTK inhibitor) in recurrent or metastatic HNSCC. PATIENTS AND METHODS: Patients received pembrolizumab 200 mg intravenously every 3 weeks, alone or in combination with acalabrutinib 100 mg orally twice daily. Safety and overall response rate (ORR) were co-primary objectives. The secondary objectives were progression-free survival (PFS) and overall survival. RESULTS: Seventy-six patients were evaluated (pembrolizumab, n = 39; pembrolizumab + acalabrutinib, n = 37). Higher frequencies of grade 3-4 treatment-emergent adverse events (AE; 65% vs. 39%) and serious AEs (68% vs. 31%) were observed with combination therapy versus monotherapy. ORR was 18% with monotherapy versus 14% with combination therapy. Median PFS was 2.7 [95% confidence interval (CI), 1.4-6.8] months in the combination arm and 1.7 (95% CI, 1.4-4.0) months in the monotherapy arm. The study was terminated due to lack of clinical benefit with combination treatment. To assess how tumor immune contexture was affected by therapy in patients with pre- and post-treatment biopsies, spatial proteomic analyses were conducted that revealed a trend toward increased CD45+ leukocyte infiltration of tumors from baseline at day 43 with pembrolizumab (monotherapy, n = 5; combination, n = 2), which appeared to be higher in combination-treated patients; however, definitive conclusions could not be drawn due to limited sample size. CONCLUSIONS: Despite lack of clinical efficacy, immune subset analyses suggest that there are additive effects of this combination; however, the associated toxicity limits the feasibility of combination treatment with pembrolizumab and acalabrutinib in patients with recurrent or metastatic HNSCC